LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Stock List・Sarepta Therapeutics Inc

Sarepta Therapeutics Inc

Closed

SectorHealthcare

17.54 -5.7

Buy Sell

Overview

Share price change

24h

Current

Min

17.52

Max

18.6

Key metrics
By Trading Economics
Income	614M 331M
Sales	288M 731M
P/E Sector Avg	55.429 51.415
EPS	3.16
Profit margin	45.287
Employees	835
EBITDA	624M 372M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+15.07% upside

Dividends
By Dow Jones
Next Earnings	5 Aug 2026

Market Stats
By TradingEconomics
Market Cap	-279M 2B
Previous open	23.24
Previous close	17.54

News Sentiment

By Acuity

100%

332 / 346 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

N/A / 62.47 Support & Resistance

Sarepta Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Jul 2025, 15:04 UTC

Major Market Movers

Sarepta Shares Rise After Company Says It Will Resume Elevidys Shipments

21 Jul 2025, 11:31 UTC

Major Market Movers

Sarepta Stock Continues to Fall After Patient Death Linked to Investigational Gene Therapy

6 May 2026, 22:50 UTC

Earnings

Sarepta Stock Sinks on Earnings Beat. Elevidys Demand Faces a Reality Check. -- Barrons.com

26 Jan 2026, 09:55 UTC

Hot Stocks

Stocks to Watch Monday: American Airlines, USA Rare Earth, RevMed -- WSJ

4 Nov 2025, 14:39 UTC

Earnings

Hot Stocks

Stocks to Watch Tuesday: Palantir, Sarepta, Tesla -- WSJ

4 Nov 2025, 12:45 UTC

Earnings

These Stocks Are Moving the Most Today: Palantir, Sarepta, Tesla, Uber, Pfizer, Norwegian Cruise Line, Amazon, AMD, and More -- Barrons.com

11 Aug 2025, 11:48 UTC

Earnings

These Stocks Are Moving the Most Today: C3.ai, Coinbase, Monday.com, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

11 Aug 2025, 11:11 UTC

Earnings

These Stocks Are Moving the Most Today: C3.ai, Coinbase, MicroStrategy, Sarepta, Avantor, Nvidia, Albemarle, and More -- Barrons.com

29 Jul 2025, 21:11 UTC

Earnings

These Stocks Moved the Most Today: SoFi, UnitedHealth, PayPal, Merck, Novo Nordisk, UPS, Sarepta, Boeing, Norfolk Southern, and More -- Barrons.com

29 Jul 2025, 12:14 UTC

Earnings

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, Novo Nordisk, UPS, Boeing, Sarepta, Whirlpool, and More -- Barrons.com

29 Jul 2025, 11:46 UTC

Earnings

These Stocks Are Moving the Most Today: SoFi, UnitedHealth, UPS, Boeing, PayPal, Sarepta, Whirlpool, and More -- Barrons.com

21 Jul 2025, 12:53 UTC

Earnings

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, Pinterest, and More -- Barrons.com

21 Jul 2025, 11:17 UTC

Earnings

These Stocks Are Moving the Most Today: Sarepta, Verizon, Block, Tesla, Domino's, Cleveland-Cliffs, and More -- Barrons.com

21 Jul 2025, 10:25 UTC

Earnings

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Domino's, Cleveland-Cliffs, Verizon, and More -- Barrons.com

21 Jul 2025, 09:50 UTC

Earnings

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

21 Jul 2025, 09:12 UTC

Earnings

These Stocks Are Moving the Most Today: Sarepta, Block, Tesla, Verizon, and More -- Barrons.com

17 Jul 2025, 16:44 UTC

Earnings

These Stocks Are Moving the Most Today: Lucid, TSMC, Elevance, Sarepta, PepsiCo, Abbott Labs, Archer Daniels, and More -- Barrons.com

17 Jul 2025, 13:48 UTC

Earnings

These Stocks Are Moving the Most Today: Lucid, TSMC, United, Sarepta, PepsiCo, Abbott Labs, MP Materials, Archer Daniels, and More -- Barrons.com

17 Jul 2025, 10:57 UTC

Earnings

These Stocks Are Moving the Most Today: TSMC, United Airlines, Sarepta, PepsiCo, GE Aerospace, MP Materials, Archer Daniels, and More -- Barrons.com

17 Jul 2025, 09:08 UTC

Hot Stocks

Stocks to Watch Thursday: TSMC, United Airlines, Sarepta -- WSJ

17 Jun 2025, 09:10 UTC

Hot Stocks

Stocks to Watch Tuesday: SunRun, Enphase Energy, Mitsubishi, Roku -- WSJ

17 Jun 2025, 08:59 UTC

Hot Stocks

Stocks to Watch Tuesday: Sunrun, Enphase Energy, Mitsubishi, Roku -- WSJ

16 Jun 2025, 08:55 UTC

Hot Stocks

Stocks to Watch: Victoria's Secret, Renault, U.S. Steel, Sarepta -- WSJ

Peer Comparison

Price change

Sarepta Therapeutics Inc Forecast

Price Target

By TipRanks

15.07% upside

12 Months Forecast

Average 21.68 USD 15.07%

High 38 USD

Low 5 USD

Based on 24 Wall Street analysts offering 12 month price targets forSarepta Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

24 ratings

Buy

Hold

Sell

Based on 24 analysts giving stock ratings to Sarepta Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 62.47Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

332 / 346 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Sarepta Therapeutics Inc

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.